LBIO (Longevity Biomedical) EPS (Basic): $ (TTM As of . 20)


What is Longevity Biomedical EPS (Basic)?

Longevity Biomedical LBIO EPS (Basic) is $ as of . 20.

Longevity Biomedical's basic earnings per share (Basic EPS) for the six months ended in . 20 was $0.00. Longevity Biomedical does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in . 20.

Longevity Biomedical's EPS (Diluted) for the six months ended in . 20 was $0.00. Longevity Biomedical does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in . 20.

Longevity Biomedical's EPS without NRI for the six months ended in . 20 was $0.00. Longevity Biomedical does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Longevity Biomedical  (NAS:LBIO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Longevity Biomedical EPS (Basic) Related Terms

Longevity Biomedical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical EPS (Basic) Chart

Longevity Biomedical Annual Data
Trend
EPS (Basic)

Longevity Biomedical Semi-Annual Data
EPS (Basic)

Longevity Biomedical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Longevity Biomedical's Basic EPS for the fiscal year that ended in . 20 is calculated as

Basic EPS (A: . 20 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-)/0
=

Longevity Biomedical's Basic EPS for the quarter that ended in . 20 is calculated as

Basic EPS (Q: . 20 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-)/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $ mean?
Longevity Biomedical (LBIO) has a EPS (Basic) of $ as of . 20. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's EPS (Basic) too high?
Longevity Biomedical's current EPS (Basic) is $.
How does Longevity Biomedical's EPS (Basic) compare to ?
Longevity Biomedical's EPS (Basic) of $ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current EPS (Basic) is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current EPS (Basic) of $. The current EPS (Basic) is $. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current EPS (Basic) is $ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.